| General Information |
| Organism |
Mus musculus, mouse |
| Cell Line Description |
DC2.4 is an immortalized murine dendritic cell line established by Z. Shen, G. Reznikoff, and their colleagues in 1997. This cell line was generated by transducing primary bone marrow cells from C57BL/6 mice with a retroviral vector that drives the co-expression of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) and the v-myc and v-raf oncogenes. Exhibiting typical dendritic cell morphology, DC2.4 cells serve as a vital in vitro model in immunological research. They are widely used to study antigen presentation, cross-priming pathways, and dendritic cell maturation cascades, as well as to screen potential vaccine candidates or cancer immunotherapies. |
| Tissue |
Bone Marrow |
| Cell Type |
Dendritic Cell (Antigen-Presenting Cell / APC) |
| Strain |
C57BL/6 |
| Disease |
Normal / Non-malignant tissue origin (Immortalized engineered line) |
| Morphology |
Dendritic / Stellate with dendritic-like processes; grows as an adherent monolayer with occasional loosely attached clustering. |
| Gender / Age |
Unspecified |
| Growth Mode |
Adherent |
| Applications |
1. A gold-standard model for analyzing the mechanisms of MHC class I and II antigen processing and presentation. 2. Elucidating the maturation process of dendritic cells using exogenous stimuli such as interferon-gamma (IFN-γ). 3. Modeling T-cell activation, cross-priming, and downstream antigen-specific CD8+ cytotoxic T-lymphocyte responses. 4. Preclinical vaccine development, evaluation of targeted delivery platforms, and validation of nucleic acid-mediated cancer immunotherapies. 5. Investigating host-pathogen interactions, innate immune pathways, and exosomal RNA communication networks. |
| Shipped In |
Dry ice |
| Storage Temperature |
−196°C (Liquid nitrogen vapor phase only) |
| Characteristics |
| Tumorigenic |
No, retains base non-malignant physiological immune properties, although it carries stable oncogenic driving fragments. |
| Transformant |
Murine GM-CSF paired with v-myc and v-raf oncogenes integrated via retroviral transfection. |
| Phenotypic Baseline |
It exhibits an immature dendritic cell phenotype under standard expansion conditions. It constitutively expresses the cell surface markers CD11c and MHC class I molecules, but shows low baseline expression levels of MHC class II molecules and costimulatory molecules such as CD40 and CD80. |
| Maturation Potential |
Highly responsive to activation. Upon stimulation (e.g., with IFN-γ or LPS), MHC class II molecules, CD40, CD80, and CCR7 are significantly upregulated, accompanied by the high-level secretion of pro-inflammatory cytokines, including IL-6, IL-12, and TNF-α. |
| Mycoplasma Test |
Negative |
| Culture Conditions and Handling |
| Subculturing |
1. Aspirate and completely discard the spent complete culture medium from the culture flask. 2. Gently rinse the cell monolayer with sterile, Ca2+/Mg2+-free PBS to remove residual traces of serum. 3. Add 1.0 to 2.0 mL of 0.25% trypsin-0.53 mM EDTA solution, ensuring the cell layer is completely covered. 4. Incubate at 37°C for 2 to 5 minutes; monitor under an inverted microscope until the cells become rounded, loosen, and completely detach from the plastic surface. 5. Quickly add an equal volume of pre-warmed complete culture medium to neutralize trypsin activity. 6. Centrifuge the cell suspension at approximately 200 × g for 5 minutes, discard the supernatant, gently resuspend the cell pellet in fresh complete culture medium, and distribute the suspension into new culture vessels. |
| Medium Renewal |
2 to 3 times per week |
| Subcultivation Ratio |
Passage cells that are in an optimal growth state and have reached confluence at a standard ratio of 1:3 to 1:6. Do not allow the cells to become over-confluent, as overcrowding may induce spontaneous differentiation. |
| Culture Conditions |
Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation |
90% Complete culture growth medium + 10% DMSO (or standard commercial Freeze Medium CM-1) |